• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于国际协议的日本SF-6Dv2估值调查。

Valuation survey for SF-6Dv2 in Japan based on the international protocol.

作者信息

Shiroiwa Takeru, Yamamoto Yosuke, Murata Tatsunori, Mulhern Brendan, Bjorner Jakob, Brazier John, Fukuda Takashi, Rowen Donna, Fukuhara Shun-Ichi

机构信息

Center for Outcomes Research and Economic Evaluation for Health (C2H), National Institute of Public Health, 2-3-6 Minami, Wako, Saitama, 351-0197, Japan.

Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan.

出版信息

Qual Life Res. 2025 Feb;34(2):445-455. doi: 10.1007/s11136-024-03830-w. Epub 2024 Nov 27.

DOI:10.1007/s11136-024-03830-w
PMID:39602017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11865146/
Abstract

PURPOSE

The SF-6D Classification System was recently updated (SF-6Dv2). We performed a valuation survey to construct a value set for the SF-6Dv2 in Japan.

METHODS

An online discrete choice experiment (DCE) with duration was used to estimate a value set for the SF-6Dv2 for Japan based on public preferences. The target sample number was 3800. Respondents were asked to complete 15 choice tasks. A conditional logit model that estimates interactions between time and each dimension was used to develop the value set.

RESULTS

The collected sample included 3933 respondents for the DCE tasks. The results of all the unconstrained models showed some inconsistencies. In particular, inconsistencies in the two most severe levels of the role limitation (RL) and vitality (VT) dimensions were observed in all models. The number of inconsistencies was smallest in a core model (n = 3) and in a model for core and common health states (n = 2). The physical functioning (PF) and pain (PA) dimensions had the greatest influence on utility at the overall level across all models. RL, VT, and social functioning (SF) had smaller overall impacts on utility. The PF weights for the two most severe levels are much lower than those in the UK and Australia. The Japanese scores tended to be lower compared with the UK SF-6Dv2 scores.

CONCLUSION

We obtained a value set for Japan (model 5). With the development of this value set, it is now possible to calculate quality-adjusted life years for economic evaluation in Japan when the SF-6Dv2 has been used.

摘要

目的

SF-6D分类系统最近进行了更新(SF-6Dv2)。我们开展了一项评估调查,以构建日本SF-6Dv2的价值集。

方法

采用一项包含持续时间的在线离散选择实验(DCE),根据公众偏好估算日本SF-6Dv2的价值集。目标样本数量为3800。要求受访者完成15项选择任务。使用估计时间与各维度之间相互作用的条件logit模型来构建价值集设定。

结果

收集到的样本包括3933名参与DCE任务的受访者。所有无约束模型的结果均显示出一些不一致性。特别是,在所有模型中均观察到角色限制(RL)和活力(VT)维度最严重的两个水平存在不一致性。在核心模型(n = 3)以及核心和常见健康状态模型(n = 2)中,不一致的数量最少。在所有模型的总体水平上,身体功能(PF)和疼痛(PA)维度对效用的影响最大。RL、VT和社会功能(SF)对效用的总体影响较小。两个最严重水平的PF权重远低于英国和澳大利亚的权重。与英国SF-6Dv2分数相比,日本分数往往较低。

结论

我们获得了日本的价值集(模型5)。随着该价值集的构建完成,当使用SF-6Dv2时,现在可以在日本计算用于经济评估的质量调整生命年。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b3c/11865146/f4bc9aae40c6/11136_2024_3830_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b3c/11865146/12daea8052e9/11136_2024_3830_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b3c/11865146/a676e78cadb2/11136_2024_3830_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b3c/11865146/0949375034e1/11136_2024_3830_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b3c/11865146/f4bc9aae40c6/11136_2024_3830_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b3c/11865146/12daea8052e9/11136_2024_3830_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b3c/11865146/a676e78cadb2/11136_2024_3830_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b3c/11865146/0949375034e1/11136_2024_3830_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b3c/11865146/f4bc9aae40c6/11136_2024_3830_Fig4_HTML.jpg

相似文献

1
Valuation survey for SF-6Dv2 in Japan based on the international protocol.基于国际协议的日本SF-6Dv2估值调查。
Qual Life Res. 2025 Feb;34(2):445-455. doi: 10.1007/s11136-024-03830-w. Epub 2024 Nov 27.
2
Valuing the SF-6Dv2 Classification System in the United Kingdom Using a Discrete-choice Experiment With Duration.采用具有持续时间的离散选择实验评估英国的 SF-6Dv2 分类系统
Med Care. 2020 Jun;58(6):566-573. doi: 10.1097/MLR.0000000000001324.
3
Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration.使用具有持续时间的离散选择实验来评估伊朗首都的 SF-6Dv2。
Qual Life Res. 2024 Jul;33(7):1853-1863. doi: 10.1007/s11136-024-03649-5. Epub 2024 Apr 17.
4
Valuing SF-6Dv2 in Australia Using an International Protocol.使用国际协议在澳大利亚评估 SF-6Dv2。
Pharmacoeconomics. 2021 Oct;39(10):1151-1162. doi: 10.1007/s40273-021-01043-4. Epub 2021 Jul 12.
5
Valuing SF-6Dv2 Using a Discrete Choice Experiment in a General Population in Quebec, Canada.在加拿大魁北克的普通人群中使用离散选择实验评估SF-6Dv2
Int J Health Policy Manag. 2024;13:8404. doi: 10.34172/ijhpm.8404. Epub 2024 Sep 7.
6
Developing a New Version of the SF-6D Health State Classification System From the SF-36v2: SF-6Dv2.从 SF-36v2 开发 SF-6D 健康状态分类系统新版本:SF-6Dv2。
Med Care. 2020 Jun;58(6):557-565. doi: 10.1097/MLR.0000000000001325.
7
Creating an SF-6Dv2 social value set for New Zealand.为新西兰制定 SF-6Dv2 社会价值集。
Soc Sci Med. 2024 Aug;354:117073. doi: 10.1016/j.socscimed.2024.117073. Epub 2024 Jun 26.
8
A new SF-6Dv2 value set based on a hybrid model using SG, cTTO, and DCE data.一种基于使用SG、cTTO和DCE数据的混合模型的新SF-6Dv2值集。
Soc Sci Med. 2025 Feb;366:117632. doi: 10.1016/j.socscimed.2024.117632. Epub 2024 Dec 14.
9
Cancer population norms using a new value set for the SF-6Dv2 based on the preferences of patients with breast or colorectal cancer in Quebec.使用基于魁北克乳腺癌或结直肠癌患者偏好的 SF-6Dv2 新效价集的癌症人群规范。
Qual Life Res. 2024 Jun;33(6):1605-1619. doi: 10.1007/s11136-024-03653-9. Epub 2024 Apr 20.
10
Valuing SF-6D Health States Using a Discrete Choice Experiment.使用离散选择实验评估SF-6D健康状态
Med Decis Making. 2014 Aug;34(6):773-86. doi: 10.1177/0272989X13503499. Epub 2013 Sep 11.

引用本文的文献

1
Mapping the EORTC QLQ-C30 and QLQ-LC13 to the SF-6D utility index in patients with lung cancer using machine learning and traditional regression methods.运用机器学习和传统回归方法将欧洲癌症研究与治疗组织核心生活质量问卷(EORTC QLQ-C30)及肺癌模块问卷(QLQ-LC13)映射到肺癌患者的SF-6D效用指数。
Health Qual Life Outcomes. 2025 Jul 1;23(1):66. doi: 10.1186/s12955-025-02394-8.
2
Health utility scores of six common cancers in China measured by SF-6Dv2.采用SF-6Dv2量表测量的中国六种常见癌症的健康效用得分。
Health Qual Life Outcomes. 2025 Jan 12;23(1):5. doi: 10.1186/s12955-025-02332-8.

本文引用的文献

1
Japanese value set for the EORTC QLU-C10D: A multi-attribute utility instrument based on the EORTC QLQ-C30 cancer-specific quality-of-life questionnaire.欧洲癌症研究与治疗组织核心生活质量问卷C10D的日本价值集:一种基于欧洲癌症研究与治疗组织QLQ-C30癌症特异性生活质量问卷的多属性效用工具。
Qual Life Res. 2024 Jul;33(7):1865-1879. doi: 10.1007/s11136-024-03655-7. Epub 2024 May 9.
2
Discrete choice experiment with duration versus time trade-off: a comparison of test-retest reliability of health utility elicitation approaches in SF-6Dv2 valuation.离散选择实验中的持续时间与时间权衡:SF-6Dv2 估值中健康效用 elicitation 方法的重测信度比较。
Qual Life Res. 2022 Sep;31(9):2791-2803. doi: 10.1007/s11136-022-03159-2. Epub 2022 May 25.
3
Development of the SF-6Dv2 health utility survey: comprehensibility and patient preference.
SF - 6Dv2健康效用调查问卷的开发:可理解性与患者偏好
J Patient Rep Outcomes. 2022 May 12;6(1):47. doi: 10.1186/s41687-022-00455-w.
4
Japanese preference weights of the Adult Social Care Outcomes Toolkit for Carers (ASCOT-Carer).日本护老者成人社会关怀结局工具包(ASCOT-Carer)的偏好权重。
Qual Life Res. 2022 Jul;31(7):2143-2151. doi: 10.1007/s11136-021-03076-w. Epub 2022 Jan 12.
5
Not all respondents use a multiplicative utility function in choice experiments for health state valuations, which should be reflected in the elicitation format (or statistical analysis).并非所有的受访者在健康状况评估的选择实验中都使用乘法效用函数,这应该反映在 elicitation format(或统计分析)中。
Health Econ. 2022 Feb;31(2):431-439. doi: 10.1002/hec.4457. Epub 2021 Nov 28.
6
Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings.日本人群 EQ-5D-5L 量表和健康效用指数 Mark 3 正常值:社区环境下疾病和症状的健康负效用目录。
Value Health. 2021 Aug;24(8):1193-1202. doi: 10.1016/j.jval.2021.03.010. Epub 2021 Apr 22.
7
Valuing SF-6Dv2 in Australia Using an International Protocol.使用国际协议在澳大利亚评估 SF-6Dv2。
Pharmacoeconomics. 2021 Oct;39(10):1151-1162. doi: 10.1007/s40273-021-01043-4. Epub 2021 Jul 12.
8
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set.癌症治疗功能评估量表 8 维度(FACT-8D),源自癌症专用 FACT-一般量表(FACT-G)的多属性效用工具:开发和澳大利亚效价设定。
Value Health. 2021 Jun;24(6):862-873. doi: 10.1016/j.jval.2021.01.007. Epub 2021 May 7.
9
Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.基于国际通用协议的 EQ-5D-Y 评估调查:日本制定价值体系。
Med Decis Making. 2021 Jul;41(5):597-606. doi: 10.1177/0272989X211001859. Epub 2021 Mar 23.
10
Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in Japan.药品和医疗器械的成本效益评估:日本新的基于价值的价格调整体系。
Int J Technol Assess Health Care. 2020 Jun;36(3):270-276. doi: 10.1017/S0266462320000264. Epub 2020 May 18.